Cancer
Roche's Lunsumio-Polivy Combination Shows Positive Results in Large B-Cell Lymphoma
A recent phase 3 study presented at the International Conference on Malignant Lymphoma has demonstrated the potential of combining the CD20xCD3 bispecific Lunsumio and the CD79b-directed ADC Polivy in treating large B-cell lymphoma (LBCL). The Lunsumio-Polivy regimen showed a significant reduction in the risk of progression or death, compared to